Ethinyl Estradiol + Desogestrel — Competitive Intelligence Brief

Ethinyl Estradiol + Desogestrel (Ethinyl Estradiol + Desogestrel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combined oral contraceptive. Area: Contraception / Reproductive Health.

marketed Combined oral contraceptive Estrogen receptor, progesterone receptor Contraception / Reproductive Health Small molecule

Target snapshot

Ethinyl Estradiol + Desogestrel (Ethinyl Estradiol + Desogestrel) — Massachusetts General Hospital. Ethinyl estradiol and desogestrel work together as a combined oral contraceptive by suppressing ovulation through hormonal feedback on the hypothalamic-pituitary-ovarian axis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ethinyl Estradiol + Desogestrel TARGET	Ethinyl Estradiol + Desogestrel	Massachusetts General Hospital	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor
fenofibrate and tibolone	fenofibrate and tibolone	Keogh Institute for Medical Research	marketed	Fibrate + Selective Estrogen Receptor Modulator (SERM)	PPAR-α (fenofibrate); Estrogen receptor, progesterone receptor, androgen receptor (tibolone)
Tibolone (Livial)	Tibolone (Livial)	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Selective tissue estrogenic activity regulator (STEAR); synthetic steroid	Estrogen receptor, progesterone receptor, androgen receptor
oral contraceptive pills	oral contraceptive pills	Kayseri Education and Research Hospital	marketed	Hormonal contraceptive	Estrogen receptor, Progesterone receptor
oral contraceptives	oral contraceptives	FHI 360	marketed	Hormonal contraceptive	Estrogen receptor, Progesterone receptor
ethinyl estradiol and cyproterone acetate	ethinyl estradiol and cyproterone acetate	S.C.B. Medical College and Hospital	marketed	Combined oral contraceptive with anti-androgenic activity	Estrogen receptor, progesterone receptor, androgen receptor
Ethinylestradiol / Dienogest	Ethinylestradiol / Dienogest	University of Palermo	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combined oral contraceptive class)

1. University of Palermo · 3 drugs in this class
2. Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
3. Organon and Co · 2 drugs in this class
4. HRA Pharma · 1 drug in this class
5. Hansoh BioMedical R&D Company · 1 drug in this class
6. Helsinki University Central Hospital · 1 drug in this class
7. Hoffmann-La Roche · 1 drug in this class
8. IVI Madrid · 1 drug in this class
9. Leiden University Medical Center · 1 drug in this class
10. Massachusetts General Hospital · 1 drug in this class